Introduction
============

Radiation therapy, especially intensity-modulated radiation therapy (IMRT) with or without concurrent chemotherapy, is the standard of care for primary nasopharyngeal carcinoma (NPC), resulting in excellent local control and overall survival (OS) rates.[@b1-ott-9-6561]--[@b5-ott-9-6561] However, local or locoregional recurrences followed by distant metastasis still represent major failure pattern, especially in patients with advanced stages.[@b6-ott-9-6561],[@b7-ott-9-6561]

Treatment for local or locoregional recurrences is challenging; various treatment options for local or locoregional recurrences have been suggested, including surgery, systemic chemotherapy, and reirradiation with various techniques. Surgery is the feasible option for nodal recurrences in patients treated primarily with IMRT and concurrent chemotherapy.[@b8-ott-9-6561] Systemic chemotherapy is the treatment of choice in metastatic NPC patients, but it is considered as a palliative option for patients with local or locoregional recurrences.[@b9-ott-9-6561] Reirradiation in the form of brachytherapy, stereotactic radiosurgery/radiation therapy, and IMRT has been used to treat local or locoregional recurrences with acceptable toxicity and progression-free survival.[@b10-ott-9-6561]--[@b12-ott-9-6561]

Previously, we reported our experience of IMRT with simultaneous modulated accelerated boost technique and concurrent chemotherapy in Saudi patients with NPC.[@b13-ott-9-6561] Herein, we report long-term follow-up of these patients, especially focusing on the pattern of failures (local, locoregional, and distant), after IMRT and concurrent chemotherapy, prognostic factors and outcomes of reirradiation, and systemic chemotherapy in Saudi patients with recurrent, metastatic NPC.

Patients and methods
====================

Study population
----------------

After the approval from the King Fahad Medical City (KFMC) Ethical Committee, this retrospective study was conducted with 68 consecutive patients with histologically proven, non-metastatic NPC, with Karnofsky performance status ≥70% and who were treated at our institute between April 2006 and December 2011. All patients provided written informed consent. All cases were evaluated through detailed history and physical examination; hematological, renal, and hepatic function tests; Epstein--Barr virus on histological specimens; and rigid nasendoscopy, magnetic resonance imaging (MRI), and computed tomography (CT) imaging of head and neck to evaluate local tumor; CT chest and abdomen, positron emission tomography imaging, and bone scan were also done to detect any distant metastasis. Additional dental and audiological assessments prior to the IMRT were also carried out.

Treatment
---------

### Radiation therapy

CT simulation was done for all patients in the supine position with thermoplastic masks for immobilization. Data were acquired with and without contrast (according to renal function tests) using 3 mm slices for planning purpose. Pre-chemotherapy MRI and CT imaging were registered with CT simulation data to delineate the tumor. The gross tumor volume (GTV) included primary (GTV-T) and nodal disease (GTV-N). High-risk clinical tumor volume (CTV-1) included GTV plus 0.5--1.0 cm margins. CTV-2 as designed for potentially involved regions included the nasopharyngeal cavity (limited only to the posterior part of nasal cavity), maxillary sinus (limited to 5 mm anterior to the posterior nasal aperture and maxillary mucosa), pterygopalatine fossa, posterior ethmoid sinus, parapharyngeal space, skull base, anterior third of clivus and cervical vertebra, inferior sphenoid sinus and cavernous sinus, and the retropharyngeal area from the base of the skull to the cranial edge of the second cervical vertebra. The CTV of the neck nodal regions included levels II, III, IV, and V, which were outlined as per Radiation Therapy Oncology Group CTV delineation guidelines for head and neck malignancies. The planning target volume was created with an additional 4 mm margin around CTV. Organs at risk including the brainstem, spinal cord, parotid glands, optic nerves, chiasm, lens, eyeballs, larynx, esophagus, temporomandibular joints, mandible, and cochlea were also contoured. Eclipse™ (Varian Medical Systems, Inc., Palo Alto, CA, USA) was used for IMRT planning. IMRT (step-and-shoot technique) was delivered by using a simultaneous-integrated boost (SIB) technique. IMRT was delivered by using an SIB technique. All patients were treated on Varian Linear Accelerator Series 2100C/D (Varian Medical Systems, Inc.), Clinac DHX (Dual High Energy) upgraded to Trilogy system. Patients' treatment plans were verified according to the criteria, distance-to-agreement (DTA) 3 mm, and dose difference 3%, using portal dosimetry and PTW 2D-ARRAY seven29 and OCTAVIUS system. The radiation dose delivered was 70 Gy in 35 fractions (2.0 Gy/d) to gross tumor (pre-chemotherapy volume), 63 Gy in 35 fractions (1.8 Gy/d) to high-risk volume, and 56 Gy in 35 fractions (1.6 Gy/d) to low-risk volume. For local or locoregional recurrent cases, reirradiation was given by SRS 25--30 Gy/five fractions or IMRT 50--60 Gy/25--30 fractions according to volume of recurrence and surrounding critical structures.

### Chemotherapy

Neoadjuvant chemotherapy was given to 56 patients, which mainly consisted of two to three cycles. Regimens used were cisplatin/docetaxel in 30 patients, cisplatin/epirubicin in 16 patients, and cisplatin/5-flourouracil in ten patients, 3-week interval prior to the initiation of IMRT. Sixty-four patients (91.2%) received concurrent chemoradiation. Concurrent chemotherapy alone was given to eight patients either weekly cisplatin 40 mg/m^2^ (40 patients) or 3-weekly cisplatin 100 mg/m^2^ (24 patients).

Follow-up
---------

The duration of follow-up was calculated from the date of diagnosis to either the date of death or the date of the last follow-up. All patients were evaluated at least once every 3 months during the first 2 years and every 6 months thereafter until death. Each follow-up included a complete history, physical examination, and rigid nasendoscopy. CT/MRI scans of the head and neck were performed at 2--3 months posttreatment and afterward as needed. Acute toxicity profile during treatment and first 3 months was assessed by Common Toxicity Criteria Version 3.0 (US Department of Health and Human Services, NIH, NCI, USA), and late toxicities were scored according to the Radiation Therapy Oncology Group radiation morbidity scoring criteria at each follow-up.

Statistical analysis
--------------------

Primary end points were patterns of failure and OS. Secondary points were locoregional control, distant metastasis control, and disease-free survival (DFS). Locoregional recurrence was defined as the time from diagnosis to reappearance of locoregional failure in irradiated field (nasopharynx or nodes). Distant metastasis control was defined as the time from diagnosis to occurrence of systemic failure. DFS was defined as the time from diagnosis to locoregional failure, distant failure, or death resulting from any cause, whichever occurred first. All survival curves were calculated by using the Kaplan--Meier method, and the difference in survival curves was compared by using the log-rank test. Different categorical variables were compared with the *χ*^2^ test. The level of significance was set at *P*\<0.05, and *P*-values were based on two-sided tests. Multivariate analysis using the Cox proportional hazard model was performed to define various potential prognostic factors.

Results
=======

Patient characteristics
-----------------------

Majority of the NPC patients had locally advanced NPC, stage IV (47.1%) and stage III (38.2%), and majority of cohort had undifferentiated histopathology (75%). Patients' characteristics are shown in [Table 1](#t1-ott-9-6561){ref-type="table"}.

Patterns of failure
-------------------

Median follow-up duration was 52.2 months (range: 11--87 months). No significant neurological or other late toxicities were documented during the follow-up period. The overall failure rate was 30.8% (21 patients) ([Table 1](#t1-ott-9-6561){ref-type="table"}). Ten patients (14.7%) had locoregional recurrences; among these, three locoregional recurrences occurred with combined distant metastasis. Among all locoregional recurrences, there were six local and four nodal recurrences ([Figure 1](#f1-ott-9-6561){ref-type="fig"}). Initial time to locoregional recurrence was 36.5 months (range: 36.5--63 months). Four patients recurred locally only (two of them were treated by reirradiation after endoscopic resection and one patient presented with extensive local recurrence, which involves base of skull and upper cervical vertebrae with pending fracture, he was unfit for surgical fixation, difficult to manipulate, and did not receive reirradiation, and the fourth one refused treatment). Three patients recurred locoregionally, two of them treated by reirradiation and the third treated by neck dissection plus reirradiation. Eleven/68 patients (16.2%) developed distant metastasis; among them three patients developed local recurrence and was salvaged with reirradiation followed by systemic chemotherapy. Two patients developed local and nodal recurrences and distant metastasis simultaneously (one of them was treated with systemic chemotherapy, while the other patient was unfit and died due to disease progression). Further, five metastatic patients were treated by systemic chemotherapy; three patients were unfit for chemotherapy, two refused treatment, and one patient had only solitary liver metastases treated by surgery alone. Reirradiation was well tolerated; acute grades 3 and 4 mucositis were observed in two of seven patients (28.6%); however, no significant late toxicities were observed. Nodal recurrences were salvaged by neck dissection.

Eleven patients (16.2%) developed distant metastases (lung, five patients; liver, two; and multiple sites, four). Initial time to distant metastasis was 16 months (range: 16--54 months). All patients with distant metastases were salvaged with systemic chemotherapy as monotherapy (paclitaxal, 5-floururacil \[PF\], three patients; taxotere (doectaxal) and cisplatin \[TP\], two patients). Systemic chemotherapy was poorly tolerated with acute grade 3--4 toxicities; neutropenia (three patients) and anemia (one patient); however, no chemotherapy-related late toxicity was observed.

A total of 16 cancer-related deaths were observed; among these, four patients with locoregional recurrences, ten patients with distant metastasis, and two patients with combined locoregional recurrences and distant metastasis died due to disease progression. The 5-year locoregional control, distant metastasis control, DFS, and OS rates of whole cohort were 81.1%, 74.3%, 60.1%, and 73.4%, respectively ([Figure 2A--D](#f2-ott-9-6561){ref-type="fig"}).

The 4-year and 5-year OS rates for locoregional recurrent NPC were 71.4% and 42.9%, respectively ([Figure 3](#f3-ott-9-6561){ref-type="fig"}). Median survival in rT2, rT3, and rT4 was 63 months, 25 months, and 14 months, respectively (*P*=0.001). Median survival in rN1 and rN2 were 40 months and 19 months, respectively (*P*=0.01). For metastatic NPC, the 2-year and 5-year-OS rates were 45.5% and 10%, respectively.

Cox regression analysis of prognostic factors in DFS rates showed that age \>40 years, male sex, stages T and N, and neoadjuvant chemotherapy were associated with DFS ([Table 2](#t2-ott-9-6561){ref-type="table"}).

Discussion
==========

In the present retrospective review, the distant metastasis was the most common pattern of failure in Saudi patients with NPC treated with IMRT with SIB technique and concurrent chemotherapy that is in agreement with international data.[@b7-ott-9-6561]--[@b9-ott-9-6561],[@b14-ott-9-6561] rT4 (especially with intracranial extension via the foramen lacerum and foramen ovale) was the predominant manifestation of locoregional recurrence, which is also in agreement with international data.[@b15-ott-9-6561] Recurrence with intracranial extension was found to have poor DFS and OS rates even after IMRT as also seen in our study.[@b16-ott-9-6561] Most of the locoregional recurrences in our study were observed in patients with male sex, advanced-stage disease, positive Epstein--Barr virus status, and in patients without chemotherapy, where efforts were done to lessen the doses to spare critical neurologic structures (optic nerve/chiasm or temporal lobe). Similar findings have been reported by a Chinese study by Kong et al.[@b17-ott-9-6561]

In our cohort, majority of patients with locoregional recurrences were treated with reirradiation via reduced-volume IMRT and stereotactic radiation therapy (SRT) with acute grade 3--4 mucositis of 28.6% without any late side effects (temporal lobe necrosis or mucosal necrosis). High incidence of acute grade 3--4 toxicities can be attributed to high volume of local recurrences and planning target volume in our cohort as compared to reported data. However, high incidence of acute grade 3--4 mucositis in reirradiation in NPC patients is not surprising, as Qiu et al reported 70.3% acute grade 3--4 toxicities,[@b18-ott-9-6561] and Han et al reported 35.7% acute grade 3--4 toxicities in recurrent NPC patients treated with reirradiation.[@b19-ott-9-6561]

The 5-year DFS and OS rates of NPC patients, especially with locoregional and distant failures in our cohort, were found in agreement with international data.[@b15-ott-9-6561],[@b18-ott-9-6561],[@b19-ott-9-6561] In recurrent NPC cases, rT stage and rN stage were found important prognostic factors for OS in our study cohort. Age was found to be an important independent prognostic factor in this study, which is also in agreement with reported literature.[@b20-ott-9-6561] Bulky recurrent disease (\>100 cm^3^) or in close proximity to critical neurological structures were treated with systemic chemotherapy alone in our cohort. Worse OS rates in our patients with metastatic disease are also in agreement with international data.[@b21-ott-9-6561]

Strengths of this study were 1) long follow-up duration, 2) accurate evaluation of extent of recurrent disease by MRI, and 3) better selection of patients for reirradiation via IMRT and SRT to minimize late toxicity. Limitations of our study were 1) retrospective data, 2) comparatively a small sample size of Saudi patients, and 3) dosimetric analysis of locoregional recurrent cases.

Conclusion
==========

Distant metastasis is the most common pattern of failure after IMRT with SIB technique with or without neoadjuvant and concurrent chemotherapy in Saudi patients with NPC. Early detection of local and locoregional recurrences is important as reirradiation with IMRT or SRT with or without chemotherapy is still feasible option with acceptable toxicity. However, efforts shall be made for proper patient selection. The volume of initial primary disease and initial T and N stages are important prognostic factors for predicting DFS. Systemic chemotherapy remains the standard treatment option for patients with bulky recurrent and metastatic NPC. However, our results need to be further tested and validated in large prospective trials.
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###### 

Patient and treatment characteristics

  Variables                                   Total study population, n (%)   Patients with locoregional and distant failures, n (%)   *P*-value
  ------------------------------------------- ------------------------------- -------------------------------------------------------- -----------
  Total patients                              68                              21                                                       
  Sex                                                                                                                                  
   Male                                       45 (66)                         14 (66.7)                                                
   Female                                     23 (44)                         7 (33.3)                                                 0.43
  Age (years)                                                                                                                          
   Median (range)                             46 (15--76)                     49.1 (42--67)                                            0.45
  Histology                                                                                                                            
   Undifferentiated carcinoma                 51 (75)                         13 (61.9)                                                0.06
   Poorly differentiated                      17 (25)                         8 (38.1)                                                 
  Initial T stage                                                                                                                      
   T1                                         13 (19.1)                       1 (4.8)                                                  
   T2                                         18 (26.4)                       4 (19.1)                                                 
   T3                                         11 (16.2)                       8 (38.1)                                                 **0.039**
   T4                                         26 (38.3)                       8 (38.1)                                                 
  Initial N stage                                                                                                                      
   N0                                         11 (16.2)                       3 (14.3)                                                 
   N1                                         22 (32.3)                       7 (33.3)                                                 
   N2                                         27 (39.7)                       7 (33.3)                                                 
   N3                                         8 (11.8)                        4 (19.1)                                                 **0.041**
  Initial AJCC staging                                                                                                                 
   I                                          3 (4.4)                         1 (4.8)                                                  
   II                                         7 (10.3)                        2 (9.6)                                                  
   III                                        26 (38.2)                       6 (28.6)                                                 
   IV                                         32 (47.1)                       12 (57.2)                                                **0.036**
  EBV status                                                                                                                           
   Negative                                   5 (7.3)                         3 (14.3)                                                 
   Positive                                   41 (60.3)                       8 (38.1)                                                 **0.01**
   Unknown                                    22 (32.4)                       10 (47.6)                                                
  Chemotherapy with initial RT                                                                                                         
   Neoadjuvant                                                                                                                         
    Cisplatin/docetaxel                       30 (44.1)                       9 (42.8)                                                 
    Carboplatin/epirubicin                    16 (23.5)                       4 (19.1)                                                 
    Cisplatin/fluorouracil                    10 (14.7)                       4 (19.1)                                                 0.29
   CCRT alone                                 8 (11.8)                        3 (14.3)                                                 
   IMRT alone                                 4 (5.9)                         1 (4.8)                                                  
  Initial RT                                                                                                                           
   Median dose (Gy)                           70                                                                                       --
   Duration (days), median (range)            44.9 (40--49)                                                                            
  Recurrent T                                                                                                                          
   rT2                                        2 (4.8)                                                                                  
   rT3                                        4 (19.1)                                                                                 --
   rT4                                        4 (19.1)                                                                                 
  Recurrent N                                                                                                                          
   rN1                                        2 (9.6)                                                                                  
   rN2                                        2 (9.6)                                                                                  
  Treatment for recurrent/metastasis                                                                                                   
   Radical RT (60 Gy/30 Fr)                   2 (9.6)                                                                                  
   Concurrent chemoradiation (60 Gy/30 Fr)    2 (9.6)                                                                                  
   SRT (1 \[30 Gy/5 Fr\], 2 \[25 Gy/5 Fr\])   3 (14.3)                                                                                 
   Systemic chemotherapy alone                14 (66.8)                                                                                

**Note:** Bold data indicate significant *P*-values.

**Abbreviations:** T, tumor; N, node; AJCC, American Joint Committee on Cancer; EBV, Epstein--Barr virus; RT, radiation therapy; CCRT, concurrent chemotherapy with IMRT; IMRT, intensity-modulated radiation therapy; Fr, fractions; SRT, stereotactic radiation therapy.

###### 

Cox regression analysis of prognostic factors affecting disease-free survival in nasopharyngeal patients

  Prognostic factor    Hazard ratio   95% CI   *P*-value
  -------------------- -------------- -------- ------------
  Age groups (years)                           
   \<40                0.8            0.6      
   \>40                1.1            0.8      **0.04**
  Sex                                          
   Male                1.3            1.0      
   Female              0.9            0.7      **0.04**
  Recurrence type                              
   Locoregional        0.9            0.8      
   Metastatic          4.2            3.8      **0.0001**
  Initial T stage                              
   T1                  1.7            1.3      
   T3                  4.2            3.8      **0.001**
  Initial N stage                              
   N0                  0.8            0.6      
   N2                  3.8            3.4      **0.001**
  Chemotherapy                                 
   Yes                 0.8            0.6      
   No                  3.8            3.4      **0.001**

**Note:** Bold data indicate significant *P*-values.

**Abbreviations:** 95% CI, 95% confidence interval; cc, cubic centimeters; T, tumor; N, node.
